Last reviewed · How we verify
Ramelteon and gabapentin
At a glance
| Generic name | Ramelteon and gabapentin |
|---|---|
| Also known as | TAK-375, Ramelteon, Neurontin®, Rozerem |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramelteon and gabapentin CI brief — competitive landscape report
- Ramelteon and gabapentin updates RSS · CI watch RSS
- Takeda portfolio CI